Literature DB >> 8031433

Treatment of acute gouty arthritis with intramuscular ketorolac tromethamine.

M Shrestha1, M J Chiu, R L Martin, J J Cush, M S Wainscott.   

Abstract

Nine consecutive patients presenting with acute gouty arthritis were treated with ketorolac 60 mg intramuscularly (IM). The average age was 58. Seven were male, and six were black. Pain was quantified in 6 of the patients using a 10-cm visual analog scale that the patients completed before and 30, 60, and 90 minutes after ketorolac administration. The mean pain score (+/- standard error of the mean) dropped from 6.43 (+/- 1.25), out of a possible 10, to 1.01 (+/- 35) (P < .01). There were no side effects of the medication. All of the patients were able to leave the treatment area satisfied with their treatment. None of the patients required crutches at discharge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031433     DOI: 10.1016/0735-6757(94)90061-2

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

Review 1.  Outcome measures in acute gout: a systematic literature review.

Authors:  Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

2.  Ketorolac tromethamine alleviates IL-1β-induced chondrocyte injury by inhibiting COX-2 expression.

Authors:  Chang Liu; Yizhi Chen
Journal:  Exp Ther Med       Date:  2022-03-18       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.